Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 60 % of short-term debt in 2023; threshold 65 %.
-
Annual account missing NBB
Fiscal year 2024 was expected before 31 July 2025 and has not been filed.
Financials
Financial year 2023
Enovis Surgical Belux from Leuven, company number BE0860800170, closed financial year 2023 with a result of € 615,345 after tax. For that financial year Enovis Surgical Belux recorded revenue of € 12.3 million and equity of € 3.3 million. Compared with financial year 2022, the result moved from € 608,549 to € 615,345. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 13, 2024.
€ 3.3 million
▲ 23% vs 2022
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 615,345
▲ 1% vs 2022
Profit after tax over the fiscal year.
€ 645,257
▲ 172% vs 2022
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2023. Retained profit grew to € 1.9 million.
People and assets in 2023
16.2
▲ 0.4 vs 2022
Average over the fiscal year, from the social balance sheet.
€ 1.9 million
▲ 14% vs 2022
€ 115,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4,067
▼ 48% vs 2022
Book value of vehicles, furniture and equipment.
Debts at end 2023
€ 4.3 million
▲ 21% vs 2022
Loans from banks and other lenders, long and short.
€ 549,284
▲ 38% vs 2022
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 21 days on average.
€ 566,960
▲ 11% vs 2022
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | Change 2022 → 2023 | |
|---|---|---|---|---|
| Revenue | € 9,809,739 | € 11,151,765 | € 12,289,616 | ▲ 10% |
| Profit after taxes | € 263,392 | € 608,549 | € 615,345 | ▲ 1% |
| Equity | € 2,057,093 | € 2,665,641 | € 3,280,987 | ▲ 23% |
| Total debts | € 4,803,266 | € 4,937,058 | € 5,905,787 | ▲ 20% |
| Cash | € 611,624 | € 237,657 | € 645,257 | ▲ 172% |
| Retained profit | € 707,093 | € 1,315,641 | € 1,930,987 | ▲ 47% |
| Bank debt | € 3,538,042 | € 3,538,000 | € 4,288,000 | ▲ 21% |
| Balance sheet total | € 6,860,358 | € 7,602,700 | € 9,186,774 | ▲ 21% |
| Employees (FTE) | 16.4 | 15.8 | 16.2 | ▲ 0.4 |
By revenue, Enovis Surgical Belux ranks 6th of 6 companies with main activity “Groothandel in farmaceutische en medische artikelen” in Leuven that publish figures (fiscal year 2023).
Key figures of Enovis Surgical Belux, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.
Ask about Enovis Surgical Belux the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Enovis Surgical Belux?
What happened at Enovis Surgical Belux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Daniel Alexis Pryor stepped down as director. NBB
- Sébastien Daniel Marc Bellart stepped down as director. NBB
- New annual accounts for financial year 2023: profit of € 615,345 (▲ 1% vs 2022). filed late Source: NBB ↗
- Daniel Alexis Pryor became a director. NBB
- Sébastien Daniel Marc Bellart became a director. NBB
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 263,392 profit in 2021 to € 615,345 profit in 2023.
Paid € 23,705 in corporate taxes since 2021.
Best year ever: 2023, with € 615,345 profit.
Pays suppliers within 21 days on average.
Management
Directors
According to the 2023 annual accounts
Daniel Alexis Pryor
Director
since 2021 · until 2028
Sébastien Daniel Marc Bellart
Director
since 2021 · until 2028
Establishments
Establishment units
Physical locations of this company
Esperantolaan 9
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Leuven
Same main activity (Groothandel in farmaceutische en medische artikelen), 15 active companies in Leuven, largest first.
€ 799.2 million revenue · 2026
€ 209 million revenue · 2026
€ 24.1 million revenue · 2025
€ 19.1 million revenue · 2024
€ 17.3 million revenue · 2025
€ 1.5 million gross margin · 2023
Details
- Company number
- 0860.800.170
- VAT number
- BE 0860.800.170
- Registered office
- Esperantolaan 9, 3001 Leuven
- Names & denominations
- Enovis Surgical Belux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 October 2003
- Peppol
- Active · Active since 15 Oct 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels